Lehrmann Elin, Afanador Zoan R, Deep-Soboslay Amy, Gallegos Gloria, Darwin William D, Lowe Ross H, Barnes Allan J, Huestis Marilyn A, Cadet Jean L, Herman Mary M, Hyde Thomas M, Kleinman Joel E, Freed William J
Cellular Neurobiology Research Branch, National Institute on Drug Abuse (NIDA IRP), National Institutes of Health, Baltimore, MD 21224, USA.
Addict Biol. 2008 Mar;13(1):105-17. doi: 10.1111/j.1369-1600.2007.00085.x. Epub 2008 Jan 14.
The present study examines the diagnostic challenges of identifying ante-mortem illicit substance use in human postmortem cases. Substance use, assessed by clinical case history reviews, structured next-of-kin interviews, by general toxicology of blood, urine and/or brain, and by scalp hair testing, identified 33 cocaine, 29 cannabis, 10 phencyclidine and nine opioid cases. Case history identified 42% cocaine, 76% cannabis, 10% phencyclidine and 33% opioid cases. Next-of-kin interviews identified almost twice as many cocaine and cannabis cases as Medical Examiner (ME) case histories, and were crucial in establishing a detailed lifetime substance use history. Toxicology identified 91% cocaine, 68% cannabis, 80% phencyclidine and 100% opioid cases, with hair testing increasing detection for all drug classes. A cocaine or cannabis use history was corroborated by general toxicology with 50% and 32% sensitivity, respectively, and with 82% and 64% sensitivity by hair testing. Hair testing corroborated a positive general toxicology for cocaine and cannabis with 91% and 100% sensitivity, respectively. Case history corroborated hair toxicology with 38% sensitivity for cocaine and 79% sensitivity for cannabis, suggesting that both case history and general toxicology underestimated cocaine use. Identifying ante-mortem substance use in human postmortem cases are key considerations in case diagnosis and for characterization of disorder-specific changes in neurobiology. The sensitivity and specificity of substance use assessments increased when ME case history was supplemented with structured next-of-kin interviews to establish a detailed lifetime substance use history, while comprehensive toxicology, and hair testing in particular, increased detection of recent illicit substance use.
本研究探讨了在人类尸检案例中识别生前非法药物使用情况的诊断挑战。通过临床病例史回顾、对近亲进行结构化访谈、血液、尿液和/或大脑的常规毒理学检测以及头皮毛发检测来评估药物使用情况,共识别出33例可卡因、29例大麻、10例苯环己哌啶和9例阿片类药物案例。病例史识别出42%的可卡因案例、76%的大麻案例、10%的苯环己哌啶案例和33%的阿片类药物案例。近亲访谈识别出的可卡因和大麻案例几乎是法医(ME)病例史的两倍,对于建立详细的终生药物使用史至关重要。毒理学检测识别出91%的可卡因案例、68%的大麻案例、80%的苯环己哌啶案例和100%的阿片类药物案例,毛发检测提高了所有药物类别的检测率。可卡因或大麻使用史经常规毒理学检测的敏感性分别为50%和32%,经毛发检测的敏感性分别为82%和64%。毛发检测对可卡因和大麻常规毒理学阳性结果的证实敏感性分别为91%和100%。病例史对可卡因毛发毒理学结果的证实敏感性为38%,对大麻的敏感性为79%,这表明病例史和常规毒理学都低估了可卡因的使用情况。在人类尸检案例中识别生前药物使用情况是病例诊断以及神经生物学疾病特异性变化特征描述的关键考虑因素。当ME病例史辅以结构化的近亲访谈以建立详细的终生药物使用史时,药物使用评估的敏感性和特异性会提高,而全面的毒理学检测,尤其是毛发检测,增加了对近期非法药物使用的检测。